Frontlight ResearchEarly access
IgA nephropathy trials in Japan
9 of 9 trials · From ClinicalTrials.gov, checked 15 November 2026. Ask the study team whether a trial fits you.
- Phase 3Taking peopleStudy to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN
- Where
- Chiba, Fukuoka, Kanazawa, Nagoya
- Age
- 2 years to 18 years
- People
- 28 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT07498335 - Phase 3Taking peopleA Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy
- Where
- Bunkyo-ku, Chiba, Chuo-shi, Fukuoka, Fukushima, Hiroshima, Kamakura-shi, Kashihara-shi, Kasugai-shi, Kawasaki-shi, Koshigaya-shi, Nagoya, Nara, Osaka, Sapporo, Sendai, Shinjuku-ku, Toyoake-shi, Yokohama, Yufu-shi
- Age
- 18 years and over
- People
- 347 worldwide
- Run by
- Takeda
See details and how to joinNCT06963827 · EU 2025-520825-19-00 - Phase 2Taking peopleA Study to Evaluate the Effect of ARGX-121 on the Change in Proteinuria in Adult Participants With IgAN
- Where
- Fukuoka, Sapporo
- Age
- 18 years and over
- People
- 120 worldwide
- Run by
- argenx
See details and how to joinNCT07773727 · EU 2026-525638-43-00 - Phase 2Taking peopleA Study to Assess the Effects of Zigakibart on IgA Nephropathy.
- Where
- Kawasaki, Miyazaki
- Age
- 18 years and over
- People
- 32 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT07146906 · EU 2024-519699-24-00 - Phase 3Taking peopleA Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)
- Where
- Ashikaga-Shi, Bunkyo-ku, Chiba, Fukushima, Hamamatsu, Hirosaki-shi, Ikeda-shi, Kashihara, Kawasaki-shi, Kitakyushu-shi, Kurashiki, Kyoto, Minato-Ku, Sagamihara-shi, Sapporo, Sendai, Shinagawa-Ku, Suita-shi, Tokushima, Toyoake-shi, Urayasu-shi, Yokohama
- Age
- 18 years and over
- People
- 454 worldwide
- Run by
- Biogen
See details and how to joinNCT06935357 · EU 2024-519345-30-00 - Phase 3Active, not recruitingA Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy
- Where
- Chiba, Kasugai, Kawasaki, Kyoto, Matsumoto, Niigata, Okayama, Ōmihachiman, Osaka, Sapporo, Sendai, Toyoake, Toyota, Yokohama
- Age
- 18 years to 100 years
- People
- 540 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT04557462 · EU 2023-508690-92-00 - Phase 3Taking peopleStudy to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Iptacopan in Pediatric Patients With Primary IgAN
- Where
- Fuchū, Kurume, Ōtsu, Toyoake
- Age
- 2 years to 18 years
- People
- 31 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT06994845 - Phase 3Taking peopleStudy of Ravulizumab in Pediatric Participants With Primary IgAN
- Where
- Wakayama
- Age
- 2 years to 18 years
- People
- 36 worldwide
- Run by
- Alexion Pharmaceuticals, Inc.
See details and how to joinNCT07024563 · EU 2024-520167-13-00 - Phase 2/3Enrolling by invitationTrial of Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy (IgAN)
- Where
- Bunkyo, Chiba, Fukuoka, Kashihara, Kawasaki-shi, Kobe, Minatoku, Miyazaki, Nagoya, Nerima-ku, Tochigi, Toyoake-shi, Tsukuba, Urayasu-shi, Yufu
- Age
- 18 years and over
- People
- 600 worldwide
- Run by
- Otsuka Pharmaceutical Development & Commercialization, Inc.
See details and how to joinNCT05248659